Accepted criteria for the definition of MDS2" were used in a total of 40 patients (23 men and 17 women, mean age 62 years). The classification of MDS according to the FAB criteria was as follows: refractory anaemia (RA) (n = 1); RA with ring sideroblasts (RARS) (n = 2); RA with excess blasts (RAEB) (n = 27); chronic myelomonocytic leukaemia (CMML) (n = 8); RAEB in transformation (RAEB-T) ( Trephine biopsy specimens of the bone marrow were taken from the posterior iliac crest2' on admission and after chemotherapy.
designated pro-and megakaryoblasts by taking morphometric measurements on smears and bone marrow sections. There was a relevant increase in the number of promegakaryoblasts in 32 patients, consistent with uncontrolled expansion of the precursor pool. Seventeen repeated bone marrow biopsy specimens taken after chemotherapy largely showed a decrease in the numbers of megakaryocytes including the precursor cell population. Moreover, morphometric evaluation disclosed that micromegakaryocytes in MDS differ significantly from those in chronic myeloid leukaemia (CML) due to distinctive nuclear features and a disturbed nuclear:cytoplasmic ratio. These changes generate a more pleomorphic or atypical appearance of this cell population in MDS, compared with micromegakaryocytes in CML.
It is concluded that the disproportionate increase in megakaryocyte precursors and the grossly abnormal aspects of micromegakaryocytes in MDS are characteristics of the severe defect involving haematopoiesis in this disorder.
Myelodysplastic syndromes (MDS) include several morphological subtypes defined by cytological criteria.' MDS may precede acute myeloid leukaemia (AML), sometimes by many years, and are further characterised by a clonal evolution, an ineffective and abnormal haematopoiesis, and variable degrees of cytopenias. Among 
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